Program
Adjuvant
Also written as “Monovalent Avian Influenza VLP (H5N1); Adjuvant”, “Matrix-M2 Adjuvant (25μg)” and “Matrix-M2 Adjuvant (50μg)”.
Its studies are mostly in Influenza, Human · Herpes Simplex · Herpes Zoster · Malaria · Respiratory Syncytial Virus Infections, led by 11 companies.
Drug pageAdjuvant: every studyMany companies study it; this page follows only the 15 they lead. All 21 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Genocea Biosciencesits history only | 30 open or running | phase 2since Apr 11, 2014 | Nov 19, 2013 | none ahead |
| BioTech Toolsits history only | 20 open or running | phase 2since Dec 7, 2011 | Apr 20, 2010 | none ahead |
| Novavaxits history only | 20 open or running | phase 1since May 2, 2012 | May 2, 2012 | none ahead |
| Colby Pharmaceuticalits history only | 10 open or running | phase 1since Apr 15, 2008 | Apr 15, 2008 | none ahead |
| Guangzhou Patronus Biotech | 11 open or running | phase 1since May 28, 2024 | May 28, 2024 | none ahead |
| Immune Targeting Systemsits history only | 10 open or running | phase 1since Oct 3, 2012 | Oct 3, 2012 | none ahead |
| MAXVAX Biotechnology Limited Liabilityits history only | 10 open or running | phase 1since Nov 16, 2022 | Nov 16, 2022 | none ahead |
| Medigen Vaccine Biologicsits history only | 10 open or running | phase 2since Apr 27, 2015 | Apr 27, 2015 | none ahead |
| Sanofiits history only | 10 open or running | phase 1since Jun 25, 2020 | Jun 25, 2020 | none ahead |
| Serum Institute of India Pvt.its history only | 11 open or running | phase 2since Aug 12, 2025 | Aug 12, 2025 | Nov 2027phase 2 · NCT07147400 |
| Yikang Biotech (Suzhou)its history only | 11 open or running | phase 1since Sep 1, 2026 | Sep 1, 2026 | Jan 22, 2027phase 1 · NCT07807449 |
Also a collaborator on its studies: Yantai Patronus Biotech.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Guangzhou Patronus Biotech only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 28, 2024First study: phase 1 study in Respiratory Syncytial Virus InfectionsFirst studyNCT06442241 · 84 enrolled · Australia
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study Guangzhou Patronus Biotech leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06442241Respiratory Syncytial Virus Infections · Australia | 1 | Active, not recruiting | Dec 30, 2025 | 84 |
How it is read
Names in the registry
- “Monovalent Avian Influenza VLP (H5N1); Adjuvant”, 6 entries
- “Matrix-M2 Adjuvant (25μg)”, 2 entries
- “Matrix-M2 Adjuvant (50μg)”, 2 entries
- “Matrix-M2 Adjuvant (75μg)”, 2 entries
- “Low dose adjuvant”, 1 entry
Conditions, from the studies’ own filings
- Influenza, Human, 6 studies
- Herpes Simplex, 2 studies
- Herpes Zoster, 1 study
- Malaria, 1 study
- Respiratory Syncytial Virus Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.